Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Ann Neurol
2014 Jan 01;751:147-54. doi: 10.1002/ana.24073.
Show Gene links
Show Anatomy links
GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy.
Lemke JR
,
Hendrickx R
,
Geider K
,
Laube B
,
Schwake M
,
Harvey RJ
,
James VM
,
Pepler A
,
Steiner I
,
Hörtnagel K
,
Neidhardt J
,
Ruf S
,
Wolff M
,
Bartholdi D
,
Caraballo R
,
Platzer K
,
Suls A
,
De Jonghe P
,
Biskup S
,
Weckhuysen S
.
???displayArticle.abstract???
OBJECTIVE: To identify novel epilepsy genes using a panel approach and describe the functional consequences of mutations.
METHODS: Using a panel approach, we screened 357 patients comprising a vast spectrum of epileptic disorders for defects in genes known to contribute to epilepsy and/or intellectual disability (ID). After detection of mutations in a novel epilepsy gene, we investigated functional effects in Xenopus laevis oocytes and screened a follow-up cohort.
RESULTS: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal epilepsy. The patient with ID and focal epilepsy had a missense mutation in the extracellular glutamate-binding domain (p.Arg540His), whereas both West syndrome patients carried missense mutations within the NR2B ion channel-forming re-entrant loop (p.Asn615Ile, p.Val618Gly). Subsequent screening of 47 patients with unexplained infantile spasms did not reveal additional de novo mutations, but detected a carrier of a novel inherited GRIN2B splice site variant in close proximity (c.2011-5_2011-4delTC). Mutations p.Asn615Ile and p.Val618Gly cause a significantly reduced Mg(2+) block and higher Ca(2+) permeability, leading to a dramatically increased Ca(2+) influx, whereas p.Arg540His caused less severe disturbance of channel function, corresponding to the milder patient phenotype.
INTERPRETATION: We identified GRIN2B gain-of-function mutations as a cause of West syndrome with severe developmental delay as well as of ID with childhood onset focal epilepsy. Severely disturbed channel function corresponded to severe clinical phenotypes, underlining the important role of facilitated NMDA receptor signaling in epileptogenesis.
Figure 1. Location of GRIN2B mutations in a schematic illustration of the conserved domains of the NR2B subunit (SP = signal peptide; ATD = amino-terminal domain, involved in receptor assembly; S1 and S2 form the ligand-binding domain; Pore = re-entrant pore-forming and transmembrane spanning domains; PDZ = PDZ domain binding motif). All
reported de novo mutations and their according phenotypes (ASD = autism spectrum disorders; FE = focal epilepsy; ID = intellectual disability; LGS = Lennox–Gastaut syndrome; Scz = schizophrenia) are listed in the top row. Mutations causing phenotypes without seizures are labeled in black, mutations in epilepsy patients are in red. So far, no
pathogenic variants have been observed in the C-terminal region of NR2B. Mutations causing West syndrome cluster within re-entrant pore-forming domain, whereas the mutation causing ID and focal epilepsy was observed in the glutamate-binding domain S1, similar to a recently described LGS case. Nonsynonymous variants that are believed not to be associated with abnormal phenotypes (gray) and are reported more than once (in brackets) in the Exome Variant Server (EVS) are listed in the bottom line.
Figure 2. Structural and functional consequences of missense mutations in GRIN2B. (A) Topology model of an NR1 and an NR2B subunit. Positions of the alterations p.Arg540His, p.Asn615Ile and p.Val618Gly are indicated by asterisks in the NR2 subunit consisting of an amino-terminal domain (ATD), the ligand-binding domain (LBD) including the S1 and S2 peptide segments, 3 transmembrane segments (M1, M2, and M3), a re-entrant pore loop (P), and an intracellular carboxy-terminal domain (CTD). Residue Arg540 lies within the glutamate-binding
domain, and Asn615 and Val618 in the ion channel pore. N = NH2-terminus; C= COOH-terminus. (B) Model of the transmembrane arrangement of the N-methyl-D-aspartate (NMDA) receptor composed of NR1 (green) and NR2B (cyan) subunits (top view). The arrow highlights the side chains of p.Asn615Ile and p.Val618Gly in the pore-forming region. (C) Gradual loss of Mg2+ inhibition of NR1-NR2B wild-type and
NR1-NR2B mutant receptor currents at −70mV. Respective sample traces of NR1-NR2B and NR1-NR2BAsn615Ile are shown above with inhibition of receptor currents by 1mM Mg2+ of NR1-NR2B (96 ± 0.9%, n=4) and mutant NR1-NR2BAsn615Ile (14 ± 7.2%, p < 0.0001, n
= 3), NR1-NR2BVal618Gly (48 ± 6.5%, p = 0.0003, n = 3), and NR1-NR2BArg540His (81 ± 3.2%, p = 0.005, n = 5) receptors. (D) Effect on Ca2+ permeability of NR1-NR2B wild-type and NR1-NR2B mutant receptor currents. Current–voltage relationships of NR1-NR2B receptors in the absence of Mg2+ in Na+-free extracellular solution reveal significant differences in the reversal potential (indicated by arrows) of NR1-NR2B (−31 ± 1.7mV, n = 4, black triangles) and mutant NR1-NR2BAsn615Ile (−1.0 ± 6.8mV,p = 0.004, n = 3, red squares),
NR1-NR2BVal618Gly (−5.4 ± 3.7mV, p < 0.001, n = 3, green squares), and NR1-NR2BArg540His (−9.4 ± 6.5mV, p = 0.013, n = 3, blue squares) receptor currents. (NMDG-Cl, N-methyl-D-glucamine chloride) Calculation of the relative divalent to monovalent cation permeability PCa/PNa by the Goldman–Hodgkin–Katz voltage equation revealed a >3-fold increase in Ca2+ permeability of the mutant NMDA receptors
(PCa/PNa for NR1-NR2B = 0.86; NR1-NR2BAsn615Ile = 5.22; NR2BVal618Gly = 3.12; and NR2BArg540His = 3.23).
Figure 3. Structural and functional analyses of the glutamate binding-domain mutation Arg540His. (A) Residue 540 is predicted to be located within the glutamate-binding S1 domain, and is significant in the stabilization of the tertiary structure of the glutamate-binding domain. (B) Substitution p.Arg540His is likely to abolish hydrogen bonding (blue
lines) with the backbone of Cys746 and His802 and a cation–pi interaction with His802, possibly leading to a relaxed fold in this region. (C) Pharmacological characterization of the apparent agonist affinities of wild-type NR1-NR2B (black triangles) and mutant NR1-NR2BArg540His
(red squares) N-methyl-D-aspartate receptors measured after heterologous expression in Xenopus laevis oocytes by 2-electrode voltage-clamping revealed that similar glutamate concentrations were required to elicit half-maximal responses (EC50 values = 0.72 ± 0.22μM and 0.31 ± 0.02μM, respectively, p = 0.14, n = 3). (D) Arg540 is a highly conserved residue within NR2A–D subunits.
Allen,
De novo mutations in epileptic encephalopathies.
2013, Pubmed
Allen,
De novo mutations in epileptic encephalopathies.
2013,
Pubmed
Berg,
Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.
2010,
Pubmed
Carvill,
GRIN2A mutations cause epilepsy-aphasia spectrum disorders.
2013,
Pubmed
de Ligt,
Diagnostic exome sequencing in persons with severe intellectual disability.
2012,
Pubmed
Edvardson,
West syndrome caused by ST3Gal-III deficiency.
2013,
Pubmed
Endele,
Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.
2010,
Pubmed
Freunscht,
Behavioral phenotype in five individuals with de novo mutations within the GRIN2B gene.
2013,
Pubmed
Furukawa,
Subunit arrangement and function in NMDA receptors.
2005,
Pubmed
Ghasemi,
The NMDA receptor complex as a therapeutic target in epilepsy: a review.
2011,
Pubmed
Hardingham,
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.
2010,
Pubmed
Kalscheuer,
Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation.
2003,
Pubmed
Kenny,
Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders.
2014,
Pubmed
Laube,
Evidence for a tetrameric structure of recombinant NMDA receptors.
1998,
Pubmed
,
Xenbase
Laube,
Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit.
1997,
Pubmed
Lemke,
Targeted next generation sequencing as a diagnostic tool in epileptic disorders.
2012,
Pubmed
Lemke,
Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes.
2013,
Pubmed
,
Xenbase
Lesca,
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.
2013,
Pubmed
Madry,
Potentiation of Glycine-Gated NR1/NR3A NMDA Receptors Relieves Ca-Dependent Outward Rectification.
2010,
Pubmed
O'Roak,
Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.
2012,
Pubmed
O'Roak,
Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations.
2011,
Pubmed
Paciorkowski,
Copy number variants and infantile spasms: evidence for abnormalities in ventral forebrain development and pathways of synaptic function.
2011,
Pubmed
Paoletti,
Molecular basis of NMDA receptor functional diversity.
2011,
Pubmed
Paoletti,
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.
2013,
Pubmed
Pettersen,
UCSF Chimera--a visualization system for exploratory research and analysis.
2004,
Pubmed
Rauch,
Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study.
2012,
Pubmed
Saitsu,
Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay.
2010,
Pubmed
Strømme,
Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX.
2002,
Pubmed
Suls,
Microdeletions involving the SCN1A gene may be common in SCN1A-mutation-negative SMEI patients.
2006,
Pubmed
Tarabeux,
Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia.
2011,
Pubmed
